Skip to content

A Retrospective Chart Review of Three Medifast Weight Control Centers

Use of the Medifast Meal Replacement Program for Weight Loss in Obese Patients: A Restrospective Chart Review of Three Medifast Weight Control Centers (MWCC)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01662830
Enrollment
446
Registered
2012-08-10
Start date
2010-04-30
Completion date
2012-03-31
Last updated
2012-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity, Meal replacements

Brief summary

The primary aim of this study is to to retrospectively evaluate the efficacy of the MWCC Jump Start (Medifast's 5 & 1) Plan on the following indices: weight loss, anthropometric changes, and reduction in common markers of coronary heart disease.

Detailed description

Portion-controlled meal replacements by themselves have been shown to be an effective weight control strategy in overweight and obese individuals. The addition of medical supervision has been shown to result in greater weight loss than meal replacements alone. MWCC provides this added support through individual weekly counseling sessions. Thus, the investigators plan to retrospectively evaluate the efficacy of the MWCC Jump Start (Medifast's 5 & 1) Plan on the following indices: weight loss, anthropometric changes, and reduction in common markers of coronary heart disease.

Interventions

None listed

Sponsors

Medifast, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Adult males and females aged 18-70 * Followed the Jump Start (5 & 1) Plan * BMI ≥ 25 * Purchased a weight management program at the MWCC location in the last 3 years * Signed patient health information consent form

Exclusion criteria

* On a plan other than the 5&1 (Jump Start) * Completed initial consultation but did not participate further * Program stopped due to client not getting baseline labs * Program stopped due for medical reasons unrelated to the 5 & 1 (Jump Start) plan * Currently an active participant at the MWCC * No signed patient health information consent form or written request to revoke consent

Design outcomes

Primary

MeasureTime frameDescription
Changes in weightweeks 4, 12, 24 and final weight loss visit (average of 19.6 weeks)Weight loss (in pounds and percent weight loss) at weeks 4, 12, 24 and at final weight loss visit (average of 19.6 weeks).
Changes in body compositionweeks 4, 12, 24 and final weight loss visit (average of 19.6 weeks)changes in lean muscle mass, body fat mass, and body fat percent at weeks 4, 12, 24, and final weight loss visit(average of 19.6 weeks).

Secondary

MeasureTime frameDescription
Goal weight achievementFinal weight loss visit (average of 19.6 weeks)The percent of clients that achieve thier goal weight by their final weight loss visit(average of 19.6 weeks)
Changes in abdominal circumference (inches)weeks 4, 12, 24 and final weight loss visit (average of 19.6 weeks)
Complianceweeks 4, 12, 24 and final weight loss visit (average of 19.6 weeks)Compliance is measured by client attendance at weekly visits, consumption of meal replacements and dietary supplements, ketone testing, and completion of food journals
Changes in cardiovascular risk factorsweeks 4, 12, 24 and final weight loss visit (average of 19.6 weeks)Improvements in diastolic and systolic blood pressure and pulse at weeks 4, 12, 24 and final weight loss visit (average of 19.6 weeks).
Maintenance of weight lossFollowing transition (up to 12 weeks) and maintenance (up to 52 weeks) phases of the program
Retention ratesweeks 4, 12, 24 and final weight loss visit (average of 19.6 weeks)Retention of clients at specified time points (weeks 4, 12, 24 and final weight loss visit) and during the transition and weight maintenance phases of the MWCC weight management program

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026